School of Medicine

Wayne State University School of Medicine

Oratorio: A Study Evaluating The Safety and Effectivness of Ocrelizumab vs Placebo in Patients With Primary Progressive MS - Closed To Enrollment

This is a 2 year study evaluating the safety and effectiveness of Ocrelizumab compared to placebo in patients with Primary Progressive MS. Patients will be randomly assigned to receive either Ocrelizumab (IV infusion) or placebo (IV infusion) every 24 weeks.


Eligibility: Patiens 18-55 years old with Primary Progressive MS and able to walk at least 20 meters without resting.


For more information visit: Oratorio